SEC Tracker
Get the app

Veradermics MANE

Veradermics FY 2025: net loss $70.0M; diluted EPS −$1,126.99

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Veradermics reported for the year ended Dec 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$70.0MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Diluted EPS−$1,126.99No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$111.9110-K income statement, on EDGAR
  3. Cash and cash equivalents$21.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$71.6MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Veradermics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.